Biora Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Biora Therapeutics Inc (BIOR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Biora Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 1,531M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-36.0% annualized vs trailing 12 months), vs decelerating (-27.4%) for its tracked peer group.
- Profitability: Its -57,506.3% net margin compares with -48.2% for the peer group.
- Peer revenue share: Biora Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.01M compares with $0.86M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BIOR Sales vs. its Competitors, Q4 2024
With a net margin of -57,506.25 %, Biora Therapeutics Inc reported lower profitability than its competitors (-48.18 %).
Biora Therapeutics Inc generated 0.01 % of the combined sales of its peer group.
Biora Therapeutics Inc vs. its Competitors, Q4 2024
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Biora Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Biora Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Biora Therapeutics Inc's competitor groups requires a Commercial License.
Biora Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Biora Therapeutics Inc | - | - | - | Yes |
| Competitors combined (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BIOR Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Amicus Therapeutics inc | 282.9% | Outperformed |
| 2 | Zymeworks Inc | 282.9% | Outperformed |
| 3 | Lifecore Biomedical Inc | 282.9% | Outperformed |
| 4 | Soleno Therapeutics Inc | 282.9% | Outperformed |
| 5 | Ardelyx inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Biora Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Biora Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Biora Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Biora Therapeutics Inc | 0.80 | 0.20 |
| Biodexa Pharmaceuticals Plc | 7,198.87 | 0.38 |
| Amicus Therapeutics inc | 4,468.19 | 632.83 |
| Soleno Therapeutics Inc | 2,813.08 | 285.01 |
| Zymeworks Inc | 1,933.59 | 37.13 |
| Ardelyx inc | 848.39 | 450.89 |
| SUBTOTAL | 17,515.69 | 1,656.76 |
Sign in to see all competitors of Biora Therapeutics Inc .
Sources: Biora Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Biora Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Biora Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Ardelyx inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Biora Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Biora Therapeutics Inc | 1 | 11,765 | -1,855,235 |
| Biodexa Pharmaceuticals Plc | 7,199 | 34,636 | -765,608 |
| Amicus Therapeutics inc | 4,468 | 1,238,411 | -53,053 |
| Soleno Therapeutics Inc | 2,813 | 1,565,978 | 527,692 |
| Zymeworks Inc | 1,934 | 140,633 | -568,152 |
| Ardelyx inc | 848 | 922,074 | -113,910 |
| PEERS TOTAL | 17,515 | 858,321 | -179,129 |
Sign in to see all peers for Biora Therapeutics Inc .
Biora Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | -0.2x | 4.5x | -4.7x |
| Return on Equity | 31.73 % | industry aggregate | 21.39 % |
| Return on Invested Capital | 45.72 % | -2.85 % (avg) | 48.57 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Biora Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenue Growth | -19.02 % | 291.78 % | -98.81 % | - |
| Operating Margin | -449.14 % | -9,449.64 % | -20,256.07 % | - |
| Return on Invested Capital | -38.45 % | 118.23 % | 100.03 % | 59.24 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Biora Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 21.4 points above the industry aggregate.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-36.0% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-27.4% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Biora Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Biora Therapeutics Inc | - | 0.17 | - |
| Biodexa Pharmaceuticals Plc | 1.39 | 2.03 | - |
| Amicus Therapeutics inc | 0.98 | 3.06 | 1.74 |
| Soleno Therapeutics Inc | 3.03 | 8.84 | 0.12 |
| Zymeworks Inc | 3.17 | 7.32 | - |
| Ardelyx inc | 0.58 | 3.80 | 1.39 |
Sign in to see all peers for Biora Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Biora Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Biora Therapeutics Inc | Q3 2024 | - | - |
| Biodexa Pharmaceuticals Plc | Q4 2025 | - | - |
| Amicus Therapeutics inc | Q4 2025 | +23.7 % | -88.5 % |
| Soleno Therapeutics Inc | Q1 2026 | - | - |
| Zymeworks Inc | Q2 2026 | -90.6 % | - |
| Ardelyx inc | Q2 2026 | +23.8 % | - |
| PEERS TOTAL | +26.4 % | - |
Sign in to see all peers for Biora Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Biora Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Biora Therapeutics Inc | Q3 2024 | - | +1,800.0 % |
| Biodexa Pharmaceuticals Plc | Q4 2025 | - | -77.1 % |
| Amicus Therapeutics inc | Q4 2025 | +80.0 % | +3.8 % |
| Soleno Therapeutics Inc | Q1 2026 | - | +700.0 % |
| Zymeworks Inc | Q2 2026 | - | - |
| Ardelyx inc | Q2 2026 | -53.6 % | -98.0 % |
Sign in to see all peers for Biora Therapeutics Inc .
Biora Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Biora Therapeutics Inc | - | - | - |
| Biodexa Pharmaceuticals Plc | - | - | - |
| Amicus Therapeutics inc | - | - | - |
| Soleno Therapeutics Inc | 18.25% | 19.51% | 22.85% |
| Zymeworks Inc | - | - | - |
| Ardelyx inc | - | - | - |
Sign in to see all peers for Biora Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Biora Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Biora Therapeutics Inc | - | 4.02 |
| Biodexa Pharmaceuticals Plc | - | 18,894.67 |
| Amicus Therapeutics inc | - | 7.06 |
| Soleno Therapeutics Inc | 29.61 | 9.87 |
| Zymeworks Inc | - | 52.08 |
| Ardelyx inc | - | 1.88 |
| PEERS AVERAGE | - | 10.57 |
Sign in to see all peers for Biora Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.